TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: X-ray exposure area product
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scatter radiation to patient and interventionist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: irradiation time for interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity of VAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of LDS signal patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Frequency of Eye Drop Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated resources required per patient to complete the main trial
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Modality of death
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of retinal nonperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Positive response to glutamate free diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Return of symptoms with MSG challenge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum tolerated dose of KML001 in combination with cisplatin
Endpoint domain: Adverse events/effects
Primary endpoint: Child linear growth: Stunting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child development z-scores based on Malawi Developmental Assessment Tool (MDAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver Reported Early Development Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cardiac repolarization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of opioid-free days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Change in Global Score of Skindex-29 QoL Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Assessment of steroid induced morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Lens Centration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal Coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Fit Acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Ultra on stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensibility of Ultra on stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in St George's respiratory questionnaire (SGRQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Short form 12 survey questionnaire (patient satisfaction and experience)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Normalized Number of Angioedema Attacks Per Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fetal renal artery pulsatile index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in chest CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Nature, incidence and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of Eribulin Mesylate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Increasing HCV RNA Level and Developing Hepatitis after Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants with Detectable Viremia and Developing Hepatitis after Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Increase (log) of HCV Viral Load between Baseline and after Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area under the concentration-time curve from time 0 to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All cause discontinuation rates
Endpoint domain: Adverse events/effects
Primary endpoint: Major Molecular Response (MMolR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients requiring hospital admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Participants With Menstrual Blood Loss Volume < 80 mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With >= 50% Reduction in MBL Volume From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obstructive Apnea Index (OAI) / Apnea Hypopnea Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Product compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Product palatability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Continuous abstinence from smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proprioceptive postural control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral Blood Flow Global
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebral Blood Flow Change Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lumefantrine plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in liver enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in platelet counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in absolute neutrophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Durable Response Rate (DRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in HgbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline proportion of PrEP users with STI-4c at one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of primary HIV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: development of severe sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequency of Cachexia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline number of circulating cancer cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement in Brain Functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time-interval weighted AUC pain ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soil-transmitted helminth re-infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Spoken language
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 24h postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimation of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Estimation of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Change of Bone Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: antipsychotic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PSA Level Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage fecal fat excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean change in maximum corneal curvature (Kmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean of Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first occurrence of all-cause mortality or cardiovascular related hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Intensity of skin reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: LV remodeling (volume and ejection fraction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the presence of necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality length of time in hospital
Endpoint domain: Mortality/survival
Primary endpoint: Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Grade 3 Adverse Reactions or Any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 24 Hours After the First Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With One or More Adverse Events of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Human bioavailability of benzoic acids and derivatives
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Human bioavailability of cinnamic acids and derivatives
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Human bioavailability of phenylpropanoid dimers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Human bioavailability of phenyl propionic acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bioavailability of benzaldehydes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exposure to Environmental Tobacco Smoke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Survival without needs of invasive ventilation at day 14
Endpoint domain: Mortality/survival
Primary endpoint: Acute Radiation induced toxicity (grade 2 or higher)
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of initial hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Very early rebleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of grade 2-4 neurotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Vineland Adaptive Behavior Scales-Third Edition (VABS-3)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Distribution Volume (VT) as Determined by [18F]-ASEM PET Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Withdrawal Score on the Minnesota Nicotine Withdrawal Scale (MNWS) on Day of PET Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving/Urge to Smoke as Determined Via the Questionnaire of Subjective Urges (QSU) on Day of PET Scan
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dosimetric accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of new diagnostic markers for BPS/IC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD34+ Endothelial Progenitor Cell number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD34+ Endothelial Progenitor Cell Migration against serum SDF1a gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene Expression of CD34+ Endothelial Progenitor Cell number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Four Square Step Test (FSST) Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Injurious Falls
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of acute groin injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Acceptability of ENG
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerability of ENG
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvements in clinical condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotection status (titers ≥40)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Solicited injection site and systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: general tolerance for the procedure and different symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detection of complications depending on the different analgosedations
Endpoint domain: Adverse events/effects
Primary endpoint: acceptance for later bronchoscopies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Individual Platelet Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of anti-LAG-3 monoclonal antibody BMS-986016
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of anti-CD137
Endpoint domain: Adverse events/effects
Primary endpoint: MTD of Anti-LAG-3 + Anti-PD-1
Endpoint domain: Adverse events/effects
Primary endpoint: MTD of Anti-CD137 + Anti-PD-1
Endpoint domain: Adverse events/effects
Primary endpoint: HDL Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Patients Receiving Biomarker Test Results
Endpoint domain: Mortality/survival
Primary endpoint: Score on Edinburgh Postnatal Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Score on the Patient Health Questionnaire-9 (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: EuroQol 5D5L
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of acute toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of chronic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in emergency room visits or hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Trough Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline in General Health Questionnaire (GHQ-28)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Outcomes of mechanical thrombectomy after acute ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PTSD Checklist 5
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Functional Well-Being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Engagement with the Application
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Comprehension of consent materials
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Transport number
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hospitalisation stay measured in days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incident cancer
Endpoint domain: Mortality/survival
Primary endpoint: Skeletal Related Events (SRE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hot Flash Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise capacity (6 minute walking test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression Scale (CES-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Zarit Burden Interview-Short Form
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Satisfaction With Life Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Stimulated Fibroblast Growth Factor 19 (FGF19)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ventilator dependent status
Endpoint domain: Mortality/survival
Primary endpoint: ultrasound results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time course and severity of MDMA discontinuation effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep data related to MDMA discontinuation effects
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Acute effects of MDMA on water and sodium homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Degree of decrease in pain assessment scales (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of melasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Caregivers' preparedness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Responder rate of 2-grade improvement in CA-SMFRS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Responder rate of 2-grade improvement in PA-SMFRS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Responder rate of 1-grade improvement in CA-SMFRS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Responder rate of 1-grade improvement in PA-SMFRS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Optimum force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Survival
Endpoint domain: Mortality/survival
Primary endpoint: Survival without event
Endpoint domain: Mortality/survival
Primary endpoint: Emotional Processing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in gut microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Active SARS-CoV-2 infection during admission
Endpoint domain: Adverse events/effects
Primary endpoint: Past SARS-CoV-2 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Hb concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area Under the Curve of Plasma Triglycerides Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in C-Reactive Protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MATRICS Neuropsychological Battery Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in PANSS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in PANSS Positive Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in PANSS Negative Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrence of NMIBC
Endpoint domain: Mortality/survival
Primary endpoint: Progression of NMIBC
Endpoint domain: Mortality/survival
Primary endpoint: Number of problems reported after discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cmax and AUC parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes